TYSABRI for Crohn's disease: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 157 adverse event reports in the FDA FAERS database where TYSABRI was used for Crohn's disease.
Most Reported Side Effects for TYSABRI
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Multiple sclerosis relapse | 811 | 9.9% | 8 | 241 |
| Fatigue | 759 | 9.2% | 0 | 56 |
| Malaise | 523 | 6.4% | 1 | 37 |
| Gait disturbance | 445 | 5.4% | 2 | 32 |
| Multiple sclerosis | 443 | 5.4% | 9 | 57 |
| Memory impairment | 422 | 5.1% | 0 | 26 |
| Headache | 368 | 4.5% | 0 | 34 |
| Drug ineffective | 329 | 4.0% | 2 | 25 |
| Asthenia | 328 | 4.0% | 3 | 49 |
| Fall | 324 | 4.0% | 8 | 99 |
| Nasopharyngitis | 310 | 3.8% | 0 | 14 |
| Urinary tract infection | 308 | 3.8% | 12 | 117 |
| Pain | 274 | 3.3% | 1 | 37 |
| Balance disorder | 260 | 3.2% | 1 | 25 |
| Hypoaesthesia | 259 | 3.2% | 0 | 32 |
Other Indications for TYSABRI
Multiple sclerosis (7,629)
Relapsing-remitting multiple sclerosis (198)
Product used for unknown indication (190)
Maternal exposure timing unspecified (15)
Exposure via father (5)
Other Drugs Used for Crohn's disease
ADALIMUMAB (99,540)
INFLIXIMAB (40,796)
VEDOLIZUMAB (28,718)
USTEKINUMAB (22,537)
RISANKIZUMAB-RZAA (12,561)
INFLIXIMAB-DYYB (10,657)
HUMIRA (10,174)
CERTOLIZUMAB PEGOL (8,758)
UPADACITINIB (4,390)
MESALAMINE (2,930)